MTH1 inhibitors for treatment of inflammatory and autoimmune conditions

US10064869B2 · kind B2 · utility

Assignee

• THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING · SE

Inventors

• Martin Scobie · Uppsala, SE
• Olov Wallner · Solna, SE
• Tobias Koolmeister · Stockholm, SE
• Karl Sven Axel Vallin · Stockholm, SE
• Carl Martin Henriksson · Bromma, SE
• Evert Homan · Sollentuna, SE
• Thomas Helleday · Stockholm, SE
• Sylvain Jacques · Val-de-Reuil, FR
• Matthieu Desroses · Knivsta, SE
• Marie-Caroline Jacques-Cordonnier · Val-de-Reuil, FR
• Roland Julius Yu Fiskesund · Kramfors, SE

Key dates

• Filing date: Jun 4, 2015
• Grant date: Sep 4, 2018
• Expiry date: Jun 4, 2035

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.